SIRT for potentially removable liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a targeted radiation treatment (SIRT) for people with liver cancer that is still confined to one side of the liver and has not been treated before. The goal is to see if SIRT can shrink the tumor enough to make surgical removal possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma) that has been confirmed by a doctor through imaging or a biopsy.
- You have not received any previous treatment for your liver cancer.
- Your tumor(s) are located in only one side of your liver (left or right lobe), and may involve a nearby branch of the portal vein or hepatic vein.
- Your liver function is good (Child-Pugh Class A) or you do not have cirrhosis, and you are generally active (able to care for yourself).
- You must be able to undergo a specialized radiation procedure called SIRT (selective internal radiation therapy) after a thorough evaluation.
- If you have hepatitis B or C, you need to be on appropriate treatment to keep the virus under control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.